Oramed Pharmaceuticals Stock Forward View - Simple Moving Average
| ORMP Stock | USD 3.26 -0.03 -0.91% |
Oramed Pharmaceuticals's price is influenced by both fundamental reality and narrative momentum. This module focuses on narrative momentum - how the current news cycle around Oramed Pharmaceuticals is likely to influence price in the short term.
Under current market conditions, the short-cycle RSI for Oramed Pharmaceuticals stands at 51, indicating neutral momentum. Values near 50 generally reflect equilibrium between upward and downward pressure.Momentum 51
Impartial
Oversold | Overbought |
Quarterly Earnings Growth 0.409 | EPS Estimate Next Quarter -0.08 | EPS Estimate Current Year 1.29 | Wall Street Target Price 6.25 | EPS Estimate Current Quarter -0.04 |
The summary frames Oramed Pharmaceuticals' price response to attention shifts and peer coverage. This section summarizes Oramed Pharmaceuticals' options flow and short interest as sentiment inputs.
Short Interest Metrics for Oramed Pharmaceuticals
Short interest data for Oramed Pharmaceuticals is reported twice a month, providing a lagged but useful view of aggregate bearish positioning in Oramed shares.
200 Day MA 2.5824 | Short Percent 0.0156 | Short Ratio 1.9 | Shares Short Prior Month 644.9 K | 50 Day MA 3.3242 |
RSI Signal: Oramed
The Simple Moving Average forecasted value of Oramed Pharmaceuticals on the next trading day is expected to be 3.27 with a mean absolute deviation of 0.10 and the sum of the absolute errors of 6.13.Hype-to-Price Context for Oramed Pharmaceuticals
Investor sentiment toward Oramed reflects the aggregated optimism or pessimism of all market participants. Extremes in Oramed Pharmaceuticals' sentiment have historically preceded significant reversals in price direction.
Overvalued stocks supported by excessive positive sentiment are vulnerable to sharp corrections when reality disappoints. Oramed Pharmaceuticals' sentiment score helps gauge how much of its current price is justified by optimism alone.
Oramed Pharmaceuticals Implied Volatility | 2.15 |
Oramed Pharmaceuticals' implied volatility is a key input in option pricing models such as Black-Scholes. It is the only forward-looking variable in these models, making it the primary driver of option premium changes not explained by price moves in Oramed Pharmaceuticals's stock.
The Simple Moving Average forecasted value of Oramed Pharmaceuticals on the next trading day is expected to be 3.27 with a mean absolute deviation of 0.10 and the sum of the absolute errors of 6.13.Oramed Pharmaceuticals after-hype prediction price | USD 3.23 |
This analysis adds an attention layer to forecasting, technical studies, analyst estimates, and earnings views.
Historical Fundamental Analysis of Oramed Pharmaceuticals can be used to cross-verify projections for Oramed Pharmaceuticals. The view supplies historical context for the projection discussion.Open Interest - Oramed Options (2026-05-15)
Open interest for Oramed Pharmaceuticals options provides a view of outstanding contracts and broader positioning context.
Oramed Pharmaceuticals Additional Predictive Modules
Most predictive techniques to examine Oramed price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Oramed using various technical indicators. When you analyze Oramed charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Oramed Pharmaceuticals Simple Moving Average Price Forecast For the 10th of March
Given 90 days horizon, the Simple Moving Average forecasted value of Oramed Pharmaceuticals on the next trading day is expected to be 3.27 with a mean absolute deviation of 0.10 , mean absolute percentage error of 0.02 , and the sum of the absolute errors of 6.13 .Please note that although there have been many attempts to predict Oramed Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Oramed Pharmaceuticals' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Oramed Pharmaceuticals Stock Forecast Pattern
| Backtest Oramed Pharmaceuticals | Oramed Pharmaceuticals Price Prediction | Research Analysis |
Oramed Pharmaceuticals Forecasted Value
This next-day forecast for Oramed Pharmaceuticals uses model performance to estimate practical downside and upside boundaries rather than a single point target alone. Investors should still remember that no empirical framework consistently proves that one family of forecasting models will outperform all other approaches in live markets.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Simple Moving Average forecasting method's relative quality and the estimations of the prediction error of Oramed Pharmaceuticals stock data series using in forecasting. Note that when a statistical model is used to represent Oramed Pharmaceuticals stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | 110.4105 |
| Bias | Arithmetic mean of the errors | -0.0162 |
| MAD | Mean absolute deviation | 0.104 |
| MAPE | Mean absolute percentage error | 0.0321 |
| SAE | Sum of the absolute errors | 6.135 |
While mean reversion in Oramed Pharmaceuticals' is a statistically observable tendency, it operates on uncertain timelines. Positions sized too aggressively against the trend can suffer sustained losses before reversion occurs.
Oramed Pharmaceuticals After-Hype Price Density Analysis
One key insight from Oramed Pharmaceuticals' price distribution analysis is that the most likely single outcome - the mode - is not necessarily the most important. The width and shape of Oramed Pharmaceuticals's distribution determine how often extreme deviations from the central forecast occur.
Next price density |
| Expected price to next headline |
Oramed Pharmaceuticals Estimiated After-Hype Price Volatility
Historical analysis of Oramed Pharmaceuticals reveals distinct patterns in how Oramed Pharmaceuticals' price responds to different categories of news. Oramed Pharmaceuticals' after-hype downside and upside margins for the prediction period are 0.16 and 7.01, respectively. The most informative signals come from news categories where Oramed Pharmaceuticals has shown consistent and predictable historical reactions.
Current Value
The after-hype framework applied to Oramed Pharmaceuticals assumes a 3 months review window and focuses on post-sentiment normalization rather than raw momentum. This view is most useful when investors want to compare sentiment-driven price extension with a more measured post-news scenario.
Oramed Pharmaceuticals Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Oramed Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Oramed Pharmaceuticals backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Oramed Pharmaceuticals, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.52 | 3.78 | 0.04 | 0.05 | 8 Events | 6 Events | In 8 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
3.26 | 3.23 | 0.00 |
|
Oramed Pharmaceuticals Hype Timeline
Oramed Pharmaceuticals is now traded for 3.26. The entity has historical hype elasticity of -0.04, and average elasticity to hype of competition of -0.05. Oramed is expected not to react to the next headline, with the price staying at about the same level, and average media hype impact volatility is over 100%. The immediate return on the next news is expected to be very small, whereas the daily expected return is now at 0.52%. %. The volatility of related hype on Oramed Pharmaceuticals is about 4200.0%, with the expected price after the next announcement by competition of 3.21. About 15.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.64. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Oramed Pharmaceuticals last dividend was issued on the 16th of January 2026. The entity completed a 1:12 stock split on 23rd of January 2013. Given the investment horizon of 90 days the next expected press release will be in 8 days. Historical Fundamental Analysis of Oramed Pharmaceuticals can be used to cross-verify projections for Oramed Pharmaceuticals. The view supplies historical context for the projection discussion.Oramed Pharmaceuticals Related Hype Analysis
Tracking the hype elasticity of Oramed Pharmaceuticals' direct competitors provides a quantified measure of how much news about other companies in the sector affects Oramed Pharmaceuticals's short-term price behavior.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| OVID | Ovid Therapeutics | 0.04 | 8 per month | 4.84 | 0.04 | 9.70 | -7.30 | 36.13 | |
| CNTX | Context Therapeutics | -0.05 | 7 per month | 3.63 | 0.33 | 10.00 | -6.88 | 24.11 | |
| CLNN | Clene Inc | -0.24 | 9 per month | 0.00 | -0.11 | 9.54 | -12.88 | 29.66 | |
| STTK | Shattuck Labs | -0.06 | 8 per month | 2.85 | 0.29 | 11.82 | -5.37 | 27.88 | |
| COYA | Coya Therapeutics Common | -0.03 | 6 per month | 0.00 | -0.1 | 4.70 | -5.27 | 17.84 | |
| MGNX | MacroGenics | -0.02 | 6 per month | 1.96 | 0.18 | 7.22 | -4.46 | 24.44 | |
| IMA | ImageneBio | -0.30 | 9 per month | 0.00 | -0.04 | 6.76 | -5.35 | 19.70 | |
| IFRX | InflaRx NV | -0.05 | 7 per month | 0.00 | -0.04 | 7.23 | -7.92 | 19.51 | |
| KLRS | Kalaris Therapeutics | -0.11 | 6 per month | 4.16 | 0.16 | 15.58 | -8.93 | 33.42 | |
| CNTB | Connect Biopharma Holdings | -0.08 | 6 per month | 0.00 | -0.01 | 8.70 | -8.00 | 23.97 |
Other Forecasting Options for Oramed Pharmaceuticals
Any investor evaluating Oramed must grapple with the challenge of interpreting Oramed Pharmaceuticals' price movement accurately. Oramed Stock price charts typically contain substantial noise that can complicate analysis and lead to poor decisions.Oramed Pharmaceuticals Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Oramed Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Oramed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Oramed Pharmaceuticals by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Oramed Pharmaceuticals Market Strength Events
Market strength indicators for Oramed Pharmaceuticals assess how the stock responds to ongoing changes in market conditions and investor sentiment. By monitoring these indicators, investors can identify the most opportune moments to trade Oramed Pharmaceuticals.
Oramed Pharmaceuticals Risk Indicators
Risk indicator analysis for Oramed Pharmaceuticals' is a critical component of accurate price forecasting and sound investment decision-making. By identifying how much risk is embedded in Oramed Pharmaceuticals' investment, investors can decide how to position and protect their exposure.
| Mean Deviation | 2.81 | |||
| Semi Deviation | 2.74 | |||
| Standard Deviation | 3.65 | |||
| Variance | 13.3 | |||
| Downside Variance | 10.46 | |||
| Semi Variance | 7.53 | |||
| Expected Short fall | -3.52 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Oramed Pharmaceuticals
Coverage intensity for Oramed Pharmaceuticals matters because narrative visibility can influence sentiment, participation, and volatility around the name. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Contributor Headline
Latest Perspective From Macroaxis
Oramed Pharmaceuticals Short Properties
Short sentiment tied to Oramed Pharmaceuticals matters because heavier bearish pressure can change how quickly future price expectations become unstable. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 40.8 M | |
| Cash And Short Term Investments | 141.9 M |
Additional Tools for Oramed Stock Analysis
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Stocks Directory Find actively traded stocks across global markets | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |